ClinicalTrials.gg
CompletedNCT00807846Updated Feb 2, 2021Results posted

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

A Phase 4 interventional study of Celecoxib and Naproxen in Arthritis, Juvenile Rheumatoid, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 39 sites in 10 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 109 studies in Arthritis, Juvenile with a site in United States — 20 open to participants now, 23 under way, 5 of them phase 3. Arthritis, Juvenile · United States.

Enrollment
12th of 83
201 · median 55
Started
2009
with 10 others
Phase 4
7 of 109
none open now
Registered
28th of 109
by date

Among the 109 studies in Arthritis, Juvenile with a site in United States, this one is the 12th largest by enrollment of the 83 interventional ones that give a count, is one of 11 that started in 2009, is one of 7 in phase 4, and was the 28th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

20 of the 109 studies in Arthritis, Juvenile with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Arthritis, Juvenile with a site in United States, or all of them as a file.
02

Study summary

This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis

03

Conditions studied

  • Arthritis, Juvenile Rheumatoid

Browse trials for

Keywords

  • Juvenile Arthritis; Juvenile Rheumatoid Arthritis;Blood Pressure;Juvenile Idiopathic Arthritis
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Polyarticular (both rheumatoid factor positive and rheumatoid factor negative),oligoarticular and extended oligoarticular JIA for ≥3 months meeting the International League of Associations for Rheumatology (ILAR) criteria for Juvenile Idiopathic Arthritis (JIA)
  • Subjects with Systemic JIA with active arthritis in at least 1 joint but without active systemic features are eligible
  • ≥2 years of age and \<18 years of age prior to the Baseline visit
  • Body weight ≥10 kg at the Baseline visit
  • Candidate for chronic NSAID therapy in the Investigator's judgment

Exclusion criteria

Exclusion Criteria:

  • Psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis types of JIA
  • Active systemic features over the prior 12 weeks in children with systemic Juvenile Idiopathic Arthritis (JIA)
  • Subjects with psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis should be excluded
  • Subjects with active Systemic JIA should not be enrolled
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Celecoxib

    Drug: Celecoxib

  • Experimental
    Naproxen

    Drug: Naproxen

Interventions

  • Celecoxib 50 mg or 100 mg PO BID for 6 weeks

  • Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Systolic Blood Pressure (SBP) at Week 6/Final Visit

    Value at 6 weeks minus value at baseline.

    Time frame: 6 Weeks/Final Visit

Secondary outcomes

  1. Change From Baseline to Week 2 in SBP.

    Value at 2 weeks minus value at baseline.

    Time frame: 2 weeks

  2. Change From Baseline in SBP at Week 4.

    Value at 4 weeks minus value at baseline.

    Time frame: 4 weeks

  3. Change From Baseline in Diastolic Blood Pressure (DBP) at Week 2.

    Value at 2 weeks minus value at baseline.

    Time frame: 2 weeks

  4. Change From Baseline in DBP at Week 4.

    Value at 4 weeks minus value at baseline.

    Time frame: 4 weeks

  5. Change From Baseline in DBP at Week 6/Final Visit

    Value at 6 weeks/Final Visit minus value at baseline.

    Time frame: 6 weeks

  6. Change From Baseline in Parent's Assessment of Overall Well-being at Week 6/Final Visit.

    The parent/legal guardian evaluated the participant's overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the visual analog scale (VAS). The VAS ranged from 0 to 100, with 0 being 'very well' and 100 being 'very poor.

    Time frame: 6 weeks

  7. Number of Participants With >= 30% Improvement in the Parent's Global Assessment of Overall Well-being at Week 6/Final Visit.

    The parent/legal guardian evaluated the participant's overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the visual analog scale (VAS). The VAS ranged from 0 to 100, with 0 being 'very well' and 100 being 'very poor.

    Time frame: Week 6/Final Visit

  8. Change From Baseline in Participant's Assessment of Overall Well-being at Week 6/Final Visit.

    Participants, ≥8 years of age at the baseline, evaluated their own overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the VAS. The VAS ranges from 0 to 100, with 0 being 'very well' and 100 being 'very poor'.

    Time frame: 6 weeks

  9. Number of Participants With >= 30% Improvement in the Participant's Global Assessment of Overall Well-being at Week 6/Final Visit.

    Participants, ≥8 years of age at the baseline, evaluated their own overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the VAS. The VAS ranges from 0 to 100, with 0 being 'very well' and 100 being 'very poor'.

    Time frame: Week 6/Final Visit

Other outcomes

  1. Change From Baseline in Assessment of Ambulatory Blood Pressure Monitoring (ABPM) for SBP and DBP at Week 6/Final Visit

    Ambulatory BP measurements were obtained from 24 participants(in addition to the BP measurements obtained by the cuff technique) participating in the exploratory 24-hour ABPM sub-study. BP was monitored by a 24 hour Ambulatory BP device provided by a central vendor.

    Time frame: 6 weeks/Final Visit

  2. Change From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit

    Ambulatory BP measurements were obtained from 24 participants (in addition to the BP measurements obtained by the cuff technique) participating in the exploratory 24-hour ABPM sub-study. A summary of ABPM 24-hour averages for heart rate is presented in this Outcome Measure.

    Time frame: 6 weeks/Final Visit

  3. Change From Baseline in Assessment of ABPM for SBP and DBP Pressure at Week 6/Final Visit (Sensitivity Analysis Excluding One Participant)

    A summary of ABPM 24-hour averages for SBP and DBP are presented in this Outcome Measure. One of the participant in the Naproxen ABPM Arm had clinically implausible high BP values at Baseline. Due to the low number of participants in each Arm (12 and 11) these values had a significant impact on the mean baseline values for the Naproxen Arm. As a result, an additional sensitivity analysis was conducted, excluding this participant (Participant ID 10031002).

    Time frame: 6 weeks/Final Visit

  4. Change From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit (Sensitivity Analysis Excluding One Participant)

    A summary of ABPM 24-hour averages for heart rate is presented in this Outcome Measure. One of the participant in the Naproxen ABPM Arm had clinically implausible high BP values at Baseline. Due to the low number of participants in each Arm (12 and 11) these values had a significant impact on the mean baseline values for the Naproxen Arm. As a result, an additional sensitivity analysis was conducted, excluding this participant (Participant ID 10031002).

    Time frame: 6 weeks/Final Visit

07

Results

Posted Nov 11, 2015

Participant flow

This was a phase 4, 6-week, randomized double-blind, multicenter, active-controlled trial in participants with juvenile idiopathic arthritis (JIA). A total of 221 participants were screened into the study in 32 investigator sites.

Participant flow — Overall Study
MilestoneCelecoxibNaproxen
Started10098
Completed8894
Not completed124
Withdrew: Adverse event50
Withdrew: Lack of efficacy20
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject21
Withdrew: Other12

Outcome measures

PrimaryChange From Baseline in Systolic Blood Pressure (SBP) at Week 6/Final Visit

Value at 6 weeks minus value at baseline.

Time frame:
6 Weeks/Final Visit
Reported as:
Least squares mean · mmHg (millimeter of mercury)
Change From Baseline in Systolic Blood Pressure (SBP) at Week 6/Final Visit
mmHg (millimeter of mercury)CelecoxibNaproxen
Change From Baseline in Systolic Blood Pressure (SBP) at Week 6/Final Visit0.366 ± 0.70-0.734 ± 0.70
Statistical analysis
  • Celecoxib vs Naproxen · ANCOVA · p = 0.274 · Mean difference (final values): 1.100 · 90% CI -0.56 to 2.76
SecondaryChange From Baseline to Week 2 in SBP.

Value at 2 weeks minus value at baseline.

Time frame:
2 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 2 in SBP.
mmHgCelecoxibNaproxen
Change From Baseline to Week 2 in SBP.-0.202 ± 0.53-1.290 ± 0.53
Statistical analysis
  • Celecoxib vs Naproxen · ANCOVA · p = 0.148 · Mean difference (final values): 1.088 · 95% CI -0.39 to 2.57
SecondaryChange From Baseline in SBP at Week 4.

Value at 4 weeks minus value at baseline.

Time frame:
4 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in SBP at Week 4.
mmHgCelecoxibNaproxen
Change From Baseline in SBP at Week 4.-0.170 ± 0.58-2.007 ± 0.58
Statistical analysis
  • Celecoxib vs Naproxen · ANCOVA · p = 0.027 · Mean difference (final values): 1.837 · 95% CI 0.21 to 3.46
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP) at Week 2.

Value at 2 weeks minus value at baseline.

Time frame:
2 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 2.
mmHgCelecoxibNaproxen
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 2.-1.346 ± 0.52-0.139 ± 0.52
Statistical analysis
  • Celecoxib vs Naproxen · ANCOVA · p = 0.106 · Mean difference (final values): -1.207 · 95% CI -2.67 to 0.26
SecondaryChange From Baseline in DBP at Week 4.

Value at 4 weeks minus value at baseline.

Time frame:
4 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in DBP at Week 4.
mmHgCelecoxibNaproxen
Change From Baseline in DBP at Week 4.-0.628 ± 0.54-0.848 ± 0.54
Statistical analysis
  • Celecoxib vs Naproxen · ANCOVA · p = 0.776 · Mean difference (final values): -0.220 · 95% CI -1.30 to 1.74
SecondaryChange From Baseline in DBP at Week 6/Final Visit

Value at 6 weeks/Final Visit minus value at baseline.

Time frame:
6 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in DBP at Week 6/Final Visit
mmHgCelecoxibNaproxen
Change From Baseline in DBP at Week 6/Final Visit-0.535 ± 0.54-0.356 ± 0.54
Statistical analysis
  • Celecoxib vs Naproxen · ANCOVA · p = 0.815 · Mean difference (final values): -0.179 · 95% CI -1.69 to 1.33
SecondaryChange From Baseline in Parent's Assessment of Overall Well-being at Week 6/Final Visit.

The parent/legal guardian evaluated the participant's overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the visual analog scale (VAS). The VAS ranged from 0 to 100, with 0 being 'very well' and 100 being 'very poor.

Time frame:
6 weeks
Reported as:
Least squares mean · mm (millimeter)
Change From Baseline in Parent's Assessment of Overall Well-being at Week 6/Final Visit.
mm (millimeter)CelecoxibNaproxen
Change From Baseline in Parent's Assessment of Overall Well-being at Week 6/Final Visit.-10.581 ± 2.081-13.614 ± 2.060
Statistical analysis
  • Celecoxib vs Naproxen · ANCOVA · p = 0.303 · Mean difference (final values): 3.033 · 95% CI -2.76 to 8.82
SecondaryNumber of Participants With >= 30% Improvement in the Parent's Global Assessment of Overall Well-being at Week 6/Final Visit.

The parent/legal guardian evaluated the participant's overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the visual analog scale (VAS). The VAS ranged from 0 to 100, with 0 being 'very well' and 100 being 'very poor.

Time frame:
Week 6/Final Visit
Reported as:
Number · Participants
Number of Participants With >= 30% Improvement in the Parent's Global Assessment of Overall Well-being at Week 6/Final Visit.
ParticipantsCelecoxibNaproxen
Number of Participants With >= 30% Improvement in the Parent's Global Assessment of Overall Well-being at Week 6/Final Visit.4754
Statistical analysis
  • Celecoxib vs Naproxen · Chi-squared · p = 0.392 · Mean difference (final values): -0.061 · 95% CI -0.202 to 0.079Mean Difference (Final Values) indicates difference in incidence (proportion) between treatments.
SecondaryChange From Baseline in Participant's Assessment of Overall Well-being at Week 6/Final Visit.

Participants, ≥8 years of age at the baseline, evaluated their own overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the VAS. The VAS ranges from 0 to 100, with 0 being 'very well' and 100 being 'very poor'.

Time frame:
6 weeks
Reported as:
Least squares mean · mm
Change From Baseline in Participant's Assessment of Overall Well-being at Week 6/Final Visit.
mmCelecoxibNaproxen
Change From Baseline in Participant's Assessment of Overall Well-being at Week 6/Final Visit.-12.990 ± 2.226-12.588 ± 2.115
Statistical analysis
  • Celecoxib vs Naproxen · ANCOVA · p = 0.897 · Mean difference (final values): -0.402 · 95% CI -6.50 to 5.69
SecondaryNumber of Participants With >= 30% Improvement in the Participant's Global Assessment of Overall Well-being at Week 6/Final Visit.

Participants, ≥8 years of age at the baseline, evaluated their own overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the VAS. The VAS ranges from 0 to 100, with 0 being 'very well' and 100 being 'very poor'.

Time frame:
Week 6/Final Visit
Reported as:
Number · Participants
Number of Participants With >= 30% Improvement in the Participant's Global Assessment of Overall Well-being at Week 6/Final Visit.
ParticipantsCelecoxibNaproxen
Number of Participants With >= 30% Improvement in the Participant's Global Assessment of Overall Well-being at Week 6/Final Visit.3345
Statistical analysis
  • Celecoxib vs Naproxen · Chi-squared · p = 0.200 · Mean difference (final values): -0.102 · 95% CI -0.257 to 0.053Mean Difference (Final Values) indicates difference in incidence (proportion) between treatments.
Other pre-specifiedChange From Baseline in Assessment of Ambulatory Blood Pressure Monitoring (ABPM) for SBP and DBP at Week 6/Final Visit

Ambulatory BP measurements were obtained from 24 participants(in addition to the BP measurements obtained by the cuff technique) participating in the exploratory 24-hour ABPM sub-study. BP was monitored by a 24 hour Ambulatory BP device provided by a central vendor.

Time frame:
6 weeks/Final Visit
Reported as:
Mean · mmHg
Change From Baseline in Assessment of Ambulatory Blood Pressure Monitoring (ABPM) for SBP and DBP at Week 6/Final Visit
mmHgCelecoxibNaproxen
SBP2.4 ± 7.02-1.7 ± 12.40
DBP0.9 ± 4.23-1.1 ± 5.36
Other pre-specifiedChange From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit

Ambulatory BP measurements were obtained from 24 participants (in addition to the BP measurements obtained by the cuff technique) participating in the exploratory 24-hour ABPM sub-study. A summary of ABPM 24-hour averages for heart rate is presented in this Outcome Measure.

Time frame:
6 weeks/Final Visit
Reported as:
Mean · bpm (beats per minute)
Change From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit
bpm (beats per minute)CelecoxibNaproxen
Change From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit2.5 ± 6.343.7 ± 8.50
Other pre-specifiedChange From Baseline in Assessment of ABPM for SBP and DBP Pressure at Week 6/Final Visit (Sensitivity Analysis Excluding One Participant)

A summary of ABPM 24-hour averages for SBP and DBP are presented in this Outcome Measure. One of the participant in the Naproxen ABPM Arm had clinically implausible high BP values at Baseline. Due to the low number of participants in each Arm (12 and 11) these values had a significant impact on the mean baseline values for the Naproxen Arm. As a result, an additional sensitivity analysis was conducted, excluding this participant (Participant ID 10031002).

Time frame:
6 weeks/Final Visit
Reported as:
Mean · mmHg
Change From Baseline in Assessment of ABPM for SBP and DBP Pressure at Week 6/Final Visit (Sensitivity Analysis Excluding One Participant)
mmHgCelecoxibNaproxen
SBP2.4 ± 7.021.9 ± 4.13
DBP0.9 ± 4.230.3 ± 2.86
Other pre-specifiedChange From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit (Sensitivity Analysis Excluding One Participant)

A summary of ABPM 24-hour averages for heart rate is presented in this Outcome Measure. One of the participant in the Naproxen ABPM Arm had clinically implausible high BP values at Baseline. Due to the low number of participants in each Arm (12 and 11) these values had a significant impact on the mean baseline values for the Naproxen Arm. As a result, an additional sensitivity analysis was conducted, excluding this participant (Participant ID 10031002).

Time frame:
6 weeks/Final Visit
Reported as:
Mean · bpm
Change From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit (Sensitivity Analysis Excluding One Participant)
bpmCelecoxibNaproxen
Change From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit (Sensitivity Analysis Excluding One Participant)2.5 ± 6.343.3 ± 8.82

Adverse events

Collected over Up to Week 6/Final Visit. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib—0/100 (0%)10/100 (10%)
Naproxen—1/98 (1%)18/98 (18.4%)
Most frequent serious events
Most frequent serious events
EventCelecoxibNaproxen
Hand fractureInjury, poisoning and procedural complications0/1001/98
Most frequent other events
Most frequent other events
EventCelecoxibNaproxen
NauseaGastrointestinal disorders4/1009/98
HeadacheNervous system disorders7/1004/98
ArthralgiaMusculoskeletal and connective tissue disorders1/1005/98

Baseline characteristics

Age, Customized
Age, Customized(Participants)CelecoxibNaproxenTotal
>=2 - <8 Years221840
>=8 - <13 Years344781
>=13 - <18 Years443377
Sex: Female, Male
Sex: Female, Male(Participants)CelecoxibNaproxenTotal
Female7664140
Male243458
08

Study locations

39 sites
  • Catalina Pointe Clinical Research, Inc.
    Tucson, Arizona 85704, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Children's Hospital-San Diego
    San Diego, California 92123, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Children's National Medical Center / Division of Rheumatology
    Washington, District of Columbia 20010, United States
  • Arthritis Associates of South Florida
    Delray Beach, Florida 33484, United States
  • Delray Research Associates
    Delray Beach, Florida 33484, United States
  • Miami Children's Hospital
    Miami, Florida 33155-3009, United States
  • Administrative Site-Hawaii Pacific Health Research Institute
    Honolulu, Hawaii 96813, United States
  • Kapiolani Medical Center for Women and Children
    Honolulu, Hawaii 96826, United States
  • Kosair Charities Pediatric Clinical Research Unit - University of Louisville
    Louisville, Kentucky 40202, United States
  • Kosair Children's Hospital
    Louisville, Kentucky 40202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • University Pediatric Rheumatology of Kentucky
    Louisville, Kentucky 40202, United States
  • Children's Hospital and Medical Center
    Omaha, Nebraska 68114, United States
  • University of Nebraska Medical Center Pediatric Research Office
    Omaha, Nebraska 68198-5456, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Hospital Roberto del Rio
    Santiago, RM 8380418, Chile
  • Hospital Regional de Concepcion Guillermo Grant Benavente
    Concepcion, VIII Region 4070038, Chile
  • Instituto de Atencion Pediatrica
    San Jose, 00000, Costa Rica
  • Clinica San Borja/Centro de Investigacion de Reumatologia
    San Borja, Lima L41, Peru
  • Clinica Ricardo Palma/Sitio de Investigacion de Reumatologia
    San Isidro, Lima L27, Peru
  • Philippine General Hospital
    Manila, 1000, Philippines
  • University of Santo Tomas Hospital
    Manila, 1008, Philippines
  • State Healthcare Institution of Moscow "Izmailovskaya City Children's Hospital"
    Moscow, 105077, Russian Federation
  • First Moscow State Medical University I.M. Sechenov of the Minzdravsocrazvitiya of Russia
    Moscow, 119992, Russian Federation
  • Smolensk Regional Clinical Hospital
    Smolensk, 214000, Russian Federation
  • SEIHPE "Smolensk State Medical Academy"of the Minzdravsocrazvitiya of Russia
    Smolensk, 214019, Russian Federation
  • Institute of Rheumatology
    Belgrade, 11000, Serbia
  • Children's Clinic of Internal Medicine
    Nis, 18000, Serbia
  • Clinical Research Unit
    Pretoria, Gauteng Province 0001, South Africa
  • CHUV - Unit of Immuno-Allergology and Rhumatology
    Ch-1011 Lausanne, Switzerland
  • Universitaets-Kinderspital
    Ch-8032 Zuerich, Switzerland
  • Department of Cardioreumatology
    Kharkiv, 61153, Ukraine
  • Institute of Pediatrics, Obstetrics and Gynecology
    Kiev, 04050, Ukraine
  • Kyiv City Children Clinical Hospital #1
    Kyiv, 04209, Ukraine
  • Crimean State Medical University, Chair of Pediatrics with a course of Children Infectious Diseases
    Simferopol, 95034, Ukraine
  • Zaporizhzhya Regional Clinical Pediatric Hospital
    Zaporizhzhya, 69063, Ukraine
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2008
First posted
Dec 12, 2008
Start
Sep 2009
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Nov 11, 2015
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00807846
Responsible party
Sponsor
First posted
Dec 12, 2008
Start date
Sep 2009
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Nov 11, 2015
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Celecoxib · Naproxen

Start the discussion